

Monthly Performance Report

December 2020

Monthly Update

In December, the portfolio rose 2.51% (after fees). This compares to the S&P/ASX200 that was up 1.21%, and the Small Ords up 2.76%. The portfolio did well to keep up with the market this month, given the cash weighting of over 20%. The portfolio returns were boosted by buying back some of the Afterpay (ASX: APT) and Kogan (ASX: KGN) sold at higher prices in October, both which rebounded sharply in December.

The 2021 financial year has so far been strong. Over six months the portfolio is up 35.63% (after fees). The S&P/ASX200 did 13.20% and the Small Ords 20.28%.

While the COVID-19 pandemic has been a once in a century experience for the world, for the markets it has been far less dramatic – with the crash of calendar year 2020 being a once in a cycle experience, and a brief one at that. In 2020 the S&P/ASX200 was down by -32.0% at its worst for the year, but it recovered to be up 1.4% at 31 December.

Monthly Portfolio Metrics

Outlook Stocks (Long)	14 Positions: 72%
Outlook Stocks (Short)	1 Positions: -2%
Event, Pair and Group (Long)	3 Positions: 10%
Event, Pair and Group (Short)	1 Positions: -1%
Cash	22%
Gross Exposure	86%
Net Exposure	78%

Return Summary Since Inception¹(after all fees)

Since Inception (p.a.)	12.60%
1 Month	2.51%
3 Months	18.97%
6 Months	35.63%
FYTD	35.63%
1 Year	31.06%
3 Years	15.37%
5 Years	8.95%
Cumulative	174.21%

Portfolio Analytics Since Inception²

Sharpe Ratio	0.65
Sortino Ratio	1.15
Standard Deviation (p.a.)	16.38%
Positive Months	62%
Maximum Drawdown	-29.10%
Avg. Gross Exposure	90.20%
Avg. Net Exposure	78.90%
Avg. Beta	0.62
Avg. VAR	1.20%

¹ Inception date is 2 July 2012. Past performance is not indicative of future performance. Returns may differ due to different tax treatments.

²Glossary of terms can be found on the Fund's website at www.monashinvestors.com/glossary/

Monthly Performance Report

December 2020

Keeping 2020 in perspective

"Prediction is difficult, especially about the future." – a quote repeated by many people, over centuries. Equity fund managers live this uncertainty daily as there is always some stock making an announcement or being buffeted by unpredictable news flow.

While over time, stock investors receive good returns from society's growing wealth, it doesn't occur in a straight line. Over the last 50 years, there has been a significant market downturn every 5 – 7 years. In one sense, around 2020 we were due for a crash. However, every one of those downturns had a different cause and played out differently.

On the other hand, one thing doesn't change at all - the continuing opportunity to make money from stocks that are at times mispriced.

Our philosophy of seeking out mispriced stocks by calculating our own DCF based valuations in the light of recurring business situations and patterns of behaviour worked well this year. We apply it bottom up on a stock by stock basis, while incorporating top down knowledge of the wider world.

In the first couple of months of 2020, before the full extent of COVID-19's reach was understood, it had already begun to have an impact on stock prices. But in an age where there is little opportunity to obtain an information advantage because communication is so good, we weren't initially in a position to judge whether the market was getting it right or not.

That changed when we were able to read between the lines of the disclosures made by the Centres for Disease Control and Prevention in the United States in late February. This led us to sell positions, and establish short positions in companies whose deteriorating business outlook impacted their valuations the most, such as in industries that relied on overseas travel or transport. It followed that our cash weighting increased from about 20% to 50% over a week, limiting the impact of the market crash on our portfolio.

When we price stocks, we estimate not just their near term cash flow, but also as best we can their outlook over many years into the future. Prices fell so fast that within a few weeks we could see a number of stocks that had attractive medium to longer term outlooks that were trading at huge discounts to our valuations, and we began to buy them. Some of these were healthcare and technology based stocks that would see their revenues and profits increase because of COVID-19. We also topped up our existing stocks that we had already thought were bargains before the crash.

As a result of buying these stocks we became fully invested, and enjoyed very strong returns in the ensuing months. The fund finished the calendar year up 31.06% after fees, well ahead of the S&P/ASX200 which was up only 1.4% and the Small Ords which was up 9.2%.

Hoping you were able to enjoy the Christmas & New Year period. Here's to a better year ahead.

Monthly Performance Report

December 2020

**For all business development enquiries, please contact
Winston Capital Partners (Acting on behalf of Monash Investors)**

SA, NT and WA Advisers	Andrew Fairweather	P: +61 401 716 043 andrew@winstoncapital.com.au
VIC, NSW and ACT Advisers	Stephen Robertson	P: +61 418 387 427 stephen@winstoncapital.com.au
VIC, QLD & NSW Advisers	Cameron Harris	P: +61 400 248 435 cameron@winstoncapital.com.au

For all investors enquiries, please contact

Link Fund Solutions Pty Limited (Acting on behalf of the Fund)
+612 9547 4311
LFS_registry@linkgroup.com

This presentation is issued by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Winston Capital Partners Pty Ltd ABN 29 159 382 813, AFSL 469 556 ("Winston Capital") for the provision of general financial product advice in relation to the Monash Absolute Investment Fund ARSN 606 855 501 ("Fund") and Monash Absolute Investment Company Limited (MA1). Monash Investors is the investment manager of the Fund and MA1. The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") is responsible entity of, and issuer of units in, the Fund. The inception date of the Fund is 2nd July 2012.

The information provided in this document is general information only and does not constitute investment or other advice. The content of this document does not constitute an offer or solicitation to subscribe for units in the Fund or an offer to buy or sell any financial product. Accordingly, reliance should not be placed on this document as the basis for making an investment, financial or other decision. This information does not take into account your investment objectives, particular needs or financial situation. Monash Investors, Winston Capital and Perpetual do not accept liability for any inaccurate, incomplete or omitted information of any kind or any losses caused by using this information. Any investment decision in connection with the Fund should only be made based on the information contained in the disclosure document for the Fund. A product disclosure statement ("PDS") issued by Perpetual dated 12 September 2017 is available for the Fund. You should obtain and consider the PDS for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. Initial Applications for units in the Fund can only be made pursuant to the application form attached to the PDS.

Performance figures assume reinvestment of income. Past performance is not a reliable indicator of future performance. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Monash Investors, Winston Capital and Perpetual do not guarantee repayment of capital or any particular rate of return from the Fund and do not give any representation or warranty as to the reliability, completeness or accuracy of the information contained in this document. All opinions and estimates included in this document constitute judgments of Monash Investors as at the date of this document are subject to change without notice. Perpetual is not responsible for this document.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme